Pictured: Renier Brentjens, Isabelle Rivière & Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, February 20, 2014

A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.

Pictured: Stem cell-derived nerve cells exposed to progerin
In the Lab
By Jennifer Bell, PhD  |  Monday, December 30, 2013

A team of Memorial Sloan Kettering scientists has come up with an approach to make stem-cell-derived neurons rapidly age in a cell culture dish. The breakthrough could transform research into Parkinson’s and other late-onset diseases.

Pictured: T cells
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 23, 2013

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the News
By Christina Pernambuco-Holsten, MA  |  Friday, December 6, 2013

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan Kettering have led to several new experimental treatments for people with cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.